Morphotek licenses ADC linker technology to Bliss Bio in China

|By:, SA News Editor

Eisai (OTCPK:ESALF)(OTCPK:ESALY) subsidiary Morphotek has out-licensed its eribulin-linker payload to China-based Bliss Biopharmaceutical Co. for the development of an discolosed antibody-drug conjugate for the Chinese market.

Under the terms of the exclusive deal, Morphotek will receive an upfront payment, milestones and royalties on net sales. Specific financial terms are not disclosed.

Subscribe for full text news in your inbox